ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer

被引:12
|
作者
Miyakawa, Kazuko [1 ]
Miyashita, Naoya [1 ]
Horie, Masafumi [2 ]
Terasaki, Yasuhiro [3 ]
Tanaka, Hidenori [4 ]
Urushiyama, Hirokazu [1 ]
Fukuda, Kensuke [1 ]
Okabe, Yugo [1 ]
Ishii, Takashi [1 ,5 ]
Kuwahara, Naomi [3 ]
Suzuki, Hiroshi, I [6 ,7 ]
Nagase, Takahide [1 ]
Saito, Akira [1 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Resp Med, Tokyo, Japan
[2] Kanazawa Univ, Grad Sch Med Sci, Dept Mol & Cellular Pathol, Kanazawa, Ishikawa, Japan
[3] Nippon Med Sch, Dept Analyt Human Pathol, Tokyo, Japan
[4] Osaka Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Osaka, Japan
[5] Univ Tokyo, Div Hlth Serv Promot, Tokyo, Japan
[6] Nagoya Univ, Ctr Neurol Dis & Canc, Div Mol Oncol, Grad Sch Med, Nagoya, Aichi, Japan
[7] Nagoya Univ, Inst Glyco Core Res iGCORE, Nagoya, Aichi, Japan
基金
日本学术振兴会;
关键词
ASCL1; miR-375; small cell lung cancer; super-enhancer; YAP1; NEUROENDOCRINE DIFFERENTIATION; YAP1; GENE; PROGRESSION; EXPRESSION; IDENTITY; PATHWAY; NEUROD1; TUMORS; NOTCH;
D O I
10.1111/cas.15481
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with dismal prognosis. Recently, molecular subtypes of SCLC have been defined by the expression status of ASCL1, NEUROD1, YAP1, and POU2F3 transcription regulators. ASCL1 is essential for neuroendocrine differentiation and is expressed in the majority of SCLC. Although previous studies investigated ASCL1 target genes in SCLC cells, ASCL1-mediated regulation of miRNAs and its relationship to molecular subtypes remain poorly explored. Here, we performed genome-wide profiling of chromatin modifications (H3K27me3, H3K4me3, and H3K27ac) by CUT&Tag assay and ASCL1 knockdown followed by RNA sequencing and miRNA array analyses in SCLC cells. ASCL1 could preferentially regulate genes associated with super-enhancers (SEs) defined by enrichment of H3K27ac marking. Moreover, ASCL1 positively regulated several SE-associated miRNAs, such as miR-7, miR-375, miR-200b-3p, and miR-429, leading to repression of their targets, whereas ASCL1 suppressed miR-455-3p, an abundant miRNA in other molecular subtypes. We further elucidated unique patterns of SE-associated miRNAs in different SCLC molecular subtypes, highlighting subtype-specific miRNA networks with functional relevance. Notably, we found apparent de-repression of common target genes of different miRNAs following ASCL1 knockdown, suggesting combinatorial action of multiple miRNAs underlying molecular heterogeneity of SCLC (e.g., co-targeting of YAP1 by miR-9 and miR-375). Our comprehensive analyses provide novel insights into SCLC pathogenesis and a clue to understanding subtype-dependent phenotypic differences.
引用
收藏
页码:3932 / 3946
页数:15
相关论文
共 50 条
  • [31] ASCL1 Regulated by HDAC1/RBBP7 Inactivates Gsk3ß to Reverse Drug Resistance in Small Cell Lung Cancer
    Guo, L.
    Zhou, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S681 - S682
  • [32] Engrailed 2 serves as a master regulator of the super-enhancer in the TNC gene locus in non-small cell lung cancer
    Li, Yan
    Jiang, Jie
    Wang, Xiaoyan
    Cao, Yong
    Tang, Li
    Song, Xueqin
    Huang, Fang
    Li, Mingying
    Chen, Feng
    Wan, Haisu
    Ye, Sujuan
    ENVIRONMENTAL TOXICOLOGY, 2024, 39 (03) : 1442 - 1455
  • [33] Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma
    Handa, Takafumi
    Hayashi, Takuo
    Ura, Ayako
    Watanabe, Isamu
    Takamochi, Kazuya
    Onagi, Hiroko
    Kishi, Monami
    Matsumoto, Naohisa
    Tajima, Ken
    Kishikawa, Satsuki
    Saito, Tsuyoshi
    Takahashi, Kazuhisa
    Suzuki, Kenji
    Yao, Takashi
    HISTOPATHOLOGY, 2023, 82 (06) : 860 - 869
  • [34] Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer
    Li, Hang
    Muhetaer, Gulizeba
    Xie, Yizi
    Yao, Kainan
    Ma, Qianqian
    Guan, Huiting
    Xing, Sizhong
    Huang, Xiufang
    Zhou, Jihong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Identification of molecular subtypes based on chromatin regulator-related genes and experimental verification of the role of ASCL1 in conferring chemotherapy resistance to breast cancer
    Li, Yilun
    Yang, Xiaolu
    Geng, Cuizhi
    Liu, Yunjiang
    Tang, Tiantian
    Zhang, Lina
    Liu, Fei
    Zhang, Meng
    Hao, Jun
    Ma, Li
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation
    Guo, Hanfei
    Li, Wenqian
    Guo, Ye
    Chen, Naifei
    Cui, Jiuwei
    CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 130 - 139
  • [37] TGFβ1 in Cancer-Associated Fibroblasts Is Associated With Progression and Radiosensitivity in Small-Cell Lung Cancer
    Zhang, Jiaqi
    Qi, Jing
    Wei, Hui
    Lei, Yuanyuan
    Yu, Hao
    Liu, Ningbo
    Zhao, Lujun
    Wang, Ping
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [38] Article MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer
    Caeser, Rebecca
    Hulton, Christopher
    Costa, Emily
    Durani, Vidushi
    Little, Megan
    Chen, Xiaoping
    Tischfield, Sam E.
    Asher, Marina
    Kombak, Faruk Erdem
    Chavan, Shweta S.
    Shah, Nisargbhai S.
    Ciampricotti, Metamia
    de Stanchina, Elisa
    Poirier, John T.
    Rudin, Charles M.
    Sen, Triparna
    ISCIENCE, 2021, 24 (11)
  • [39] Dynamic Transition of Molecular Subtypes in Relapsed Small Cell Lung Cancer Treated with Multimodal Therapy
    Yasuda, K.
    Haruki, T.
    Miyamoto, T.
    Ohshima, Y.
    Matsui, S.
    Kubouchi, Y.
    Nakamura, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S688 - S689
  • [40] Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway
    Tan, Mingyue
    Pan, Qi
    Gong, Hua
    Zhai, Xinyu
    Wan, Zhong
    Ge, Minyao
    Gu, Jianyi
    Zhang, Dingguo
    Chen, Xia
    Xu, Dongliang
    PHARMACOLOGICAL RESEARCH, 2023, 197